Justice Department Briefing 2026-07-29
Estimated reading time: 7 minutes
1. Agency Information Collection Activities; Proposed eCollection, eComments Requested; Proposed New Collection Request; Title-Suspicious Orders of Controlled Substances
Sub: Justice Department
Content: The Drug Enforcement Administration (DEA), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
2. Agency Information Collection Activities; Proposed eCollection eComments Requested; Title-Medical History and Examination
Sub: Justice Department
Content: The Drug Enforcement Administration, Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
3. Agency Information Collection Activities; Proposed Collection; Comments Requested; Firearms Transaction Record-ATF Form 5300.9 and 5300.9A (“Form 4473”)
Sub: Justice Department
Content: The Department of Justice (DOJ), Bureau of Alcohol, Tobacco, Firearms, and Explosives (ATF), will be submitting the following information collection request (ICR) to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995 (PRA). The proposed information collection was previously published in the Federal Register, 91 FR 25448, on May 8, 2026, allowing a 60-day comment period. This interim notice informs the public that ATF is requesting that OMB extend the existing ICR 1140- 0020 without change. ATF will be publishing the usual second notice for a 30-day public comment period on proposed changes to the ICR thereafter. ATF received comments on the proposed changes to Form 4473 under this ICR that it needs some time to address. In addition, because some of the proposed changes and comments reflect proposed revisions to associated regulations \1\ whose public comment period does not end until a month after the 60-day ICR comment period ended, ATF needs additional time to assess those comments as well. However, the existing ICR is expiring at the end of August and thus does not afford sufficient time before it expires. As a result, ATF is publishing this interim notice to inform the public that it will be requesting that OMB extend the existing ICR without change while it addresses public comments, and will follow up with the normal 30-day notice to complete the PRA renewal process for the ICR's proposed changes. The request to extend the existing ICR is necessary to ensure continuity while ATF considers the public comments, so that federal firearms licensees continue to have a valid form on which to record firearms transactions in accordance with applicable regulations. In the subsequent 30-day notice, ATF will summarize as usual the public comments it received on the ICR's proposed changes, provide responses, and note any changes that might result. The public will have 30 days to then submit comments to OMB on the ICR, as per the usual PRA process. —————————————————————————
4. Gene M. Koop, D.D.S.; Decision and Order
Link: https://www.federalregister.gov/documents/2026/07/28/2026-15201/gene-m-koop-dds-decision-and-order
Sub: Justice Department, Drug Enforcement Administration
5. Kerri Zavota, DVM; Decision and Order
Link: https://www.federalregister.gov/documents/2026/07/28/2026-15199/kerri-zavota-dvm-decision-and-order
Sub: Justice Department, Drug Enforcement Administration
6. Notice of Lodging of Proposed Consent Decree
Sub: Justice Department
7. United States v. Edwards LifeSciences Corp. and Genesis MedTech Group Limited; Proposed Final Judgment and Competitive Impact Statement
Sub: Justice Department, Antitrust Division
8. Bulk Manufacturer of Controlled Substances Application: American Radiolabeled Chem
Sub: Justice Department, Drug Enforcement Administration
Content: American Radiolabeled Chem has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
9. United States, et al. v. OhioHealth Corporation; Proposed Final Judgment and Competitive Impact Statement
Sub: Justice Department, Antitrust Division
10. Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Previously Approved Collection; Title-Recordkeeping for Partial fills of Prescriptions
Sub: Justice Department
Content: The Drug Enforcement Administration (DEA), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
11. Agency Information Collection Activities; Proposed eCollection, eComments Requested; Revision of a Previously Approved Collection; Title-Recordkeeping for the Transfer of Electronic Prescriptions in Schedules III-V between Pharmacies
Sub: Justice Department
Content: The Drug Enforcement Administration (DEA), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
12. Agency Information Collection Activities; Proposed eCollection, eComments Requested; Extension Without Change of a Previously Approved Collection; Title-U.S. Official Order Forms for Schedules I and II Controlled Substances DEA Form 222
Sub: Justice Department
Content: The Drug Enforcement Administration (DEA), Department of Justice (DOJ), will be submitting the following information collection request to the Office of Management and Budget (OMB) for review and approval in accordance with the Paperwork Reduction Act of 1995.
Legal Disclaimer
This article includes content collected from the Federal Register (federalregister.gov). The content is not an official government publication. This article is for informational purposes only and does not constitute legal advice. For case-specific consultation, please contact us. Read our full Legal Disclaimer, which also includes information on translation accuracy.
